FDA greenlights LivaNova's nerve stimulation device for epilepsy

The Food and Drug Administration on Friday approved the newest version of LivaNova's Vagus Nerve Stimulation Therapy System.

The system, used to treat patients with drug-resistant epilepsy, includes the SenTiva implantable generator and a small tablet device used to program the device based on the patient's treatment needs.

Sentiva can detect and treat seizures before they start, or stop seizures that have already begun by sending electrical impulses to the vagus nerve. The system also collects events commonly associated with seizures, such as heart rate variations or a patient's body position.

More articles on supply chain:

Express Scripts to acquire eviCore for $3.6B: 4 things to know
This startup will deliver defibrillators to 911 callers via drone
4 drug, devicemakers in the headlines

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars